Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120219 | 1.00 | CA1 (0.44) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL4423649 | 0.83 | CA2 (0.45) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL333923 | 0.83 | CA2 (0.45) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL17048988 | 0.79 | CA2 (0.41) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL17046823 | 0.79 | CA2 (0.41) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL17046824 | 0.79 | CA2 (0.41) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL513626 | 0.73 | PPARG (0.47) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL5973925 | 0.73 | PPARG (0.47) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL513627 | 0.73 | PPARG (0.47) | CA1CA2PRSS1PRSS2PRSS3 | |
| SCHEMBL11831525 | 0.72 | KMT2A (0.54) | MAPTALDH1A1TDP1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113039175-B | Method for preparing arylsulfonyl acrylonitrile | 凯米拉公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-115477611-A | MRGPRX2 antagonists for the treatment of pseudoallergy | 香港大学 | 2022-12-16 | — | — | CN | disclosed |
| WO-2011130395-A1 | INHIBITORS OF FLIP TO TREAT CANCER | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989495-B2 | 3-Sulfonyl propenenitriles, e.g., BAY 11-7085 (3-(t-butylphenylsulfonyl)-2-propenenitrile; promoting apoptosis and inhibiting readhesion of cancer cells; antimetastasis agents, particularly for hepatic, parietal or peritoneal area; inhibiting tumorigenesis; antiproliferative agents (not for myeloma) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2281077-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | University of Utah Research Foundation (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124272-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| WO-2003072038-A2 | COMPOSITIONS AND METHODS FOR INHIBITING NF-κB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NFKBIA, RELA, NFKB1 | CA1 1475/4885CA2 3319/4885PRSS1 2809/4885 |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | NFKBIA, IKBKB, RELA | CA1 872/4885CA2 2897/4885PRSS1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.